Tharimmune Corp (THAR) - Forward P/S Multiple
Tharimmune, Inc. (THAR) is mitigating regulatory risks by developing a diversified portfolio of drugs to combat cancer and skin pathologies. The forward price-to-sales ratio visualizes market expectations, where the level captures the current state. The company's ecosystem focuses on pruritus therapy and liver diseases. The business is currently at the start of clinical trials and relies exclusively on venture capital investments.
Summary analytical data breakdowns for Tharimmune Corporation (THAR)
- current price and projected stock value:
- market capitalization indicators:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
THAR - Company Net Income|Future Profit Tharimmune, Inc.|THAR - Company Value to Net Income|Forward P/E Multiple Tharimmune Corp|THAR - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tharimmune Corporation|THAR - Operating profit before amortization|Net earnings per share (EPS TTM) Tharimmune|THAR - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months tharimmune.com|THAR - Expected net earnings per share growth this year|Expected earnings per share growth for next year Tharimmune, Inc.
- company sales and revenue statistics:
Analysis of all company metrics:Tharimmune (THAR)
The selection of promising issuers is based on comparing market value with expected cash flows using multiples. The forward P/S ratio reflects the relationship between current capitalization and projected revenue; however, for Tharimmune, Inc. (THAR), this calculation is complicated by geopolitical barriers hindering clinical trials and drug certification, making the forward P/S ratio trend a critical indicator of market optimism.
Competitors of Tharimmune, Inc.
Forward P/S Multiple ONC (BeiGene)|Forward Price to Sales HALO|RevMed - Forward P/S Multiple|AAPG - Forward P/S Multiple|CG Oncology, Inc. (CGON) - Price-to-Projected Revenue Ratio|urogen.com - Forward Price to Sales|BCAX (Bicara Therapeutics) - Forward P/S Multiple|Personalis Inc (PSNL) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Erasca Corp (ERAS)|Forward Price-to-Revenue Multiple Delcath Corp DCTH|Price-to-Projected Revenue Ratio Y-mAbs Therapeutics YMAB|AURA - Forward Price-to-Revenue Multiple|CADL: Forward Price-to-Revenue Multiple|ARAY - Forward P/S Multiple|sellaslifesciences.com (SLS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ACTU|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio TuHURA HURA|Forward Price-to-Revenue Multiple TARA (Protara Therapeutics, Inc.)|FATE (Fate Therapeutics Inc) - Forward Price to Sales|Forward P/S Multiple WHWK (Aadi Bioscience)|Market Cap to Expected Sales Ratio TScan Therapeutics Inc (TCRX)|CSBR - Price-to-Projected Revenue Ratio|XBIT (XBiotech Inc.) - Market Cap to Projected Revenue|CVM: Forward P/S Multiple|Forward Price-to-Revenue Multiple OS Therapies Inc.|Forward Price-to-Revenue Multiple RADX|Artiva (ARTV) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple ANL (Adlai Nortye Ltd.)|Price to Expected Revenue Ratio VERU|Forward P/S Multiple TPST (Tempest Therapeutics, Inc.)|Forward Price to Sales XLO|Enochian BioSciences - Forward P/S Multiple|MURA - Forward P/S Multiple|kairospharma.com (KAPA) - Price-to-Projected Revenue Ratio|OnKure Therapeutics - Forward Price to Sales|GDTC (CytoMed Therapeutics Ltd) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Curis Corp (CRIS)|Forward P/S Multiple APLM|Forward P/S Multiple advanbiomed.com (ADVB)|Price-to-Projected Revenue Ratio Genprex, Inc. GNPX|CLDI: Market Cap to Projected Revenue|Sunshine Biopharma, Inc. - Forward P/S Multiple|Xenetic Biosciences (XBIO) - Forward Price-to-Revenue Multiple|SLRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Kitov Pharma (PPBT)|Price-to-Projected Revenue Ratio American Oncology Network Inc|BGNE: Forward Price to Sales|Forward Price-to-Revenue Multiple CKPT (Checkpoint Therapeutics, Inc.)|ELEV (elevationoncology.com) - Forward Price to Sales|Forward P/S Multiple ICAD (iCAD)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|VIRX - Forward P/S Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Inc - Forward Price to Sales|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple
